It is also worth investigating whether anti-IL-17 or anti-IL-17R biologics and corticosteroids in combination could slower the progression of IPF in the clinical setting to clarify the causal or mediation relationships amongst IL-17, GR-β and response to corticosteroids. The gene discussed is IL17RA; the disease is idiopathic pulmonary fibrosis.